National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, 20892, United States
NCT Number: NCT00001928
Patients with Parkinson's disease have low levels of the neurotransmitter dopamine. Dopamine is responsible for motor function and normal physical activity. Patients with Parkinson's disease typically suffer from tremors, rigid muscles, stooped postures, and walk with a shuffle. The drug levodopa acts as a replacement for dopamine and has been has been used effectively for over 30 years as treatment for Parkinsons disease. Because of its effectiveness, levodopa has been used to distinguish Parkinson's disease from other conditions that may resemble Parkinson's disease.
Traditionally, levodopa has been given as a pill. In this study, researchers would like to inject levodopa directly into a vein (intravenous) in order to diagnose cases of Parkinson's disease. This method provides immediate results and allows doctors to adjust the dose of levodopa very carefully. Because the intravenous method of giving levodopa is less practical than oral medication, it is not an available alternative for the routine treatment of Parkinson's disease. However, it may be useful for faster diagnosis of the disease and for determining effective doses of oral medication.
Looking for future studies?
Notify MeAll sexes
Observational
Bethesda, Maryland, 20892, United States
A positive response to levodopa is now considered a condition sine qua non for the diagnosis of idiopathic Parkinson's disease. Under this protocol, patients with parkinsonism of uncertain etiology will be tested for their motor response to intravenous levodopa to aid in the diagnosis of Parkinson's disease. This protocol regulates and stipulates the acute administration of intravenous levodopa and associated safety issues.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
All patients will have parkinsonism of undetermined etiology.
Males and females between the ages of 18 and 85 are eligible for the study.
No presence or history of any medical condition that can reasonably be expected to subject the patient to unwarranted risks, specifically those who have the following: a history of convulsive, hepatic, or renal disorders; currently receiving treatment for myocardial infarction, arrhythmia or cardiac failure; and pregnant women or anyone not practicing an effective means of birth control.
National Institute of Neurological Disorders and Stroke (NINDS)
Nih
Intravenous Levodopa in Parkinsonism
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01715727
Basal Ganglia Diseases, Brain Diseases
TaoYuan County, Taiwan
View Trial DetailsNCT00273351
Basal Ganglia Diseases, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT00096720
Basal Ganglia Diseases, Brain Diseases
Oxnard, California, United States
View Trial DetailsNCT00129181
Basal Ganglia Diseases, Brain Diseases
Innsbruck, Austria
View Trial Details